ProCE Banner Activity

TH3RESA Final Results: T-DM1 vs Physician’s Choice for HER2+ MBC

Slideset Download
Conference Coverage
Use of trastuzumab emtansine improved survival in women with metastatic breast cancer and previous experience of anti-HER2 therapies compared with physician-selected therapy.

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation